Open Questions: Therapeutics

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Therapeutics'
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Smart catheters
📑 0.50 💥 0.50
open ⚖ 1500
Self-complementary AAV
📑 0.50 💥 0.50
open ⚖ 1500
Enhanced capsids
📑 0.50 💥 0.50
open ⚖ 1500
Regulatable expression
📑 0.50 💥 0.50
open ⚖ 1500
Pharmacogenomics
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Does combined maresin analog plus senolytic agent treatment eliminate senescent microglia while preserving non-senescent cells, or does it cause unacceptable off-target toxicity that limits its therap
📑 0.50 💥 0.50
open ⚖ 1500
Can extracellular vesicle-based mitochondrial transfer therapies achieve sufficient brain penetration and neuronal specificity through systemic delivery using current LAMP2B targeting approaches?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal dosing regimen for chronic AD treatment?
📑 0.50 💥 0.50
open ⚖ 1500
Optimal dosing**: What is the optimal dose for efficacy while maintaining safety?
📑 0.50 💥 0.50
open ⚖ 1500
Clinical outcomes**: Will tau reduction translate to cognitive benefit?
📑 0.50 💥 0.50
open ⚖ 1500
Long-term safety**: What is the optimal duration of treatment?
📑 0.50 💥 0.50
open ⚖ 1500
Combination trials
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding
📑 0.50 💥 0.50
open ⚖ 1500
Larger AD trials
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection**: Which patients are most likely to respond?
📑 0.50 💥 0.50
open ⚖ 1500
Targeting moieties
📑 0.50 💥 0.50
open ⚖ 1500
Cargo loading optimization
📑 0.50 💥 0.50
open ⚖ 1500
Phase III Trials
📑 0.50 💥 0.50
open ⚖ 1500
Risdiplam ([risdiplam](/therapeutics/risdiplam))
📑 0.50 💥 0.50
open ⚖ 1500
Novel ASO chemistries
📑 0.50 💥 0.50
open ⚖ 1500
Closed-loop systems
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Protein engineering
📑 0.50 💥 0.50
open ⚖ 1500
Multi-target approaches
📑 0.50 💥 0.50
open ⚖ 1500
Precision medicine
📑 0.50 💥 0.50
open ⚖ 1500
Mitochondrial condensates
📑 0.50 💥 0.50
open ⚖ 1500
Nucleolar stress
📑 0.50 💥 0.50
open ⚖ 1500
LLPS modulators + autophagy enhancers
📑 0.50 💥 0.50
open ⚖ 1500
Brain-organoid derived exosomes
📑 0.50 💥 0.50
open ⚖ 1500
Exosome-based combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
MRI-guided delivery
📑 0.50 💥 0.50
open ⚖ 1500
Glutamate antagonists
📑 0.50 💥 0.50
open ⚖ 1500
OX2R-selective agonists
📑 0.50 💥 0.50
open ⚖ 1500
Long-acting formulations
📑 0.50 💥 0.50
open ⚖ 1500
Continuous delivery
📑 0.50 💥 0.50
open ⚖ 1500
CB1 positive allosteric modulators (PAMs)
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy protocols
📑 0.50 💥 0.50
open ⚖ 1500
Combination with other modalities
📑 0.50 💥 0.50
open ⚖ 1500
Modular platforms
📑 0.50 💥 0.50
open ⚖ 1500
Positive allosteric modulators
📑 0.50 💥 0.50
open ⚖ 1500
Subunit-selective compounds
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Dementia with Lewy bodies
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Automated Quantification
📑 0.50 💥 0.50
open ⚖ 1500
Epidemiology
📑 0.50 💥 0.50
open ⚖ 1500
Prevention trials
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-guided treatment
📑 0.50 💥 0.50
open ⚖ 1500
Subcutaneous formulations
📑 0.50 💥 0.50
open ⚖ 1500
Novel Targets
📑 0.50 💥 0.50
open ⚖ 1500
Wireless Systems
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism Elucidation
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Optimization
📑 0.50 💥 0.50
open ⚖ 1500
Clinical Translation
📑 0.50 💥 0.50
open ⚖ 1500
Trojan horse liposomes
📑 0.50 💥 0.50
open ⚖ 1500
Gene delivery:
📑 0.50 💥 0.50
open ⚖ 1500
Wireless systems:
📑 0.50 💥 0.50
open ⚖ 1500
Closed-loop:
📑 0.50 💥 0.50
open ⚖ 1500
Combination:
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Formulation optimization
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule tau modulators
📑 0.50 💥 0.50
open ⚖ 1500
Combination regimens
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic studies
📑 0.50 💥 0.50
open ⚖ 1500
Disease stage optimization
📑 0.50 💥 0.50
open ⚖ 1500
Early intervention
📑 0.50 💥 0.50
open ⚖ 1500
Cleavage-resistant pro-neurotrophins
📑 0.50 💥 0.50
open ⚖ 1500
biased agonists
📑 0.50 💥 0.50
open ⚖ 1500
Intranasal delivery
📑 0.50 💥 0.50
open ⚖ 1500
CNS-selective analogs
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic Modulation
📑 0.50 💥 0.50
open ⚖ 1500
Observational Studies
📑 0.50 💥 0.50
open ⚖ 1500
Multiple sclerosis
📑 0.50 💥 0.50
open ⚖ 1500
Genetic stratification
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Patient stratification
📑 0.50 💥 0.50
open ⚖ 1500
Combination formulations
📑 0.50 💥 0.50
open ⚖ 1500
Blood Sugar Effects
📑 0.50 💥 0.50
open ⚖ 1500
Selective mTORC1 inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
Gene integration
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Combination potential
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Stem cell delivery
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Composite AI endpoints
📑 0.50 💥 0.50
open ⚖ 1500
Physiological biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Optimal timing and dosing
📑 0.50 💥 0.50
open ⚖ 1500
Combination strategies
📑 0.50 💥 0.50
open ⚖ 1500
Genetic stratification
📑 0.50 💥 0.50
open ⚖ 1500
Can digital adherence tools and caregiver coaching improve real-world effect size?
📑 0.50 💥 0.50
open ⚖ 1500
How can meal-pattern intervention trials be designed for advanced dysphagic populations without high attrition?
📑 0.50 💥 0.50
open ⚖ 1500
Are there genotype-dependent responses (for example, [APOE](/proteins/apoe)-stratified effects)?
📑 0.50 💥 0.50
open ⚖ 1500
Which component drives most benefit: lipid quality, polyphenol load, fiber diversity, or adherence consistency?
📑 0.50 💥 0.50
open ⚖ 1500
Can Mediterranean/MIND adherence reduce progression velocity in biomarker-defined AD or PSP subgroups?
📑 0.50 💥 0.50
open ⚖ 1500
Can engineered mitochondria containing SPM biosynthetic machinery be successfully delivered to microglia via nanoparticles and integrate into native cellular machinery without triggering cellular toxi
📑 0.50 💥 0.50
open ⚖ 1500
Does pharmacological enhancement of Miro1 activity improve or worsen neurodegeneration outcomes in animal models, given that Miro1 degradation is protective in Parkinson's disease?
📑 0.50 💥 0.50
open ⚖ 1500
Can selective pharmacological enhancement of Miro1 activity be achieved without causing mitochondrial aggregation, excessive transport, and increased oxidative stress?
📑 0.50 💥 0.50
open ⚖ 1500
Does inhibition of BNIP3/NIX mitophagy in donor cells increase net functional mitochondrial transfer in vivo, or does it cause accumulation of dysfunctional mitochondria that offsets potential benefit
📑 0.50 💥 0.50
open ⚖ 1500
Could pharmacological restoration of delta-catenin expression or function reverse the cognitive and synaptic deficits, and would such intervention be relevant for treating Cri-du-Chat syndrome or Alzh
📑 0.50 💥 0.50
open ⚖ 1500
Which specific branches of the kynurenine pathway are most therapeutically relevant for targeted intervention in distinct neurological, neurodegenerative, and neuropsychiatric disorders?
📑 0.50 💥 0.50
open ⚖ 1500
How can region-specific differences in BBB vascularization and permeability be leveraged to develop targeted therapeutic strategies for vulnerable brain regions?
📑 0.50 💥 0.50
open ⚖ 1500
Can interventions that reduce reliance on habitual performance (e.g., increasing voluntary/goal-directed control) delay or prevent PD onset in high-risk individuals?
📑 0.50 💥 0.50
open ⚖ 1500
Can the optimized pan-SMN enhancer virus be adapted for safe and effective therapeutic delivery in human neurodegenerative disease contexts?
📑 0.50 💥 0.50
open ⚖ 1500
What are the long-term expression profiles and potential immunogenic responses to these AAV-delivered enhancer constructs in non-human primates?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Broader indications
📑 0.50 💥 0.50
open ⚖ 1500
Patient stratification
📑 0.50 💥 0.50
open ⚖ 1500
Brain shuttle antibodies
📑 0.50 💥 0.50
open ⚖ 1500
Vectorized antibodies
📑 0.50 💥 0.50
open ⚖ 1500
Conformational specificity
📑 0.50 💥 0.50
open ⚖ 1500
Disease-modifying therapies
📑 0.50 💥 0.50
open ⚖ 1500
CBS vs PSP differences**: Do protocols need tailoring?
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
Closed-loop systems
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specific promoters
📑 0.50 💥 0.50
open ⚖ 1500
Regulatable expression systems
📑 0.50 💥 0.50
open ⚖ 1500
Next-generation AAV vectors
📑 0.50 💥 0.50
open ⚖ 1500
Trivalent CARs
📑 0.50 💥 0.50
open ⚖ 1500
Switchable CARs
📑 0.50 💥 0.50
open ⚖ 1500
Combinatorial Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Universal CAR Platforms
📑 0.50 💥 0.50
open ⚖ 1500
With Anti-Tau Therapy
📑 0.50 💥 0.50
open ⚖ 1500
With Anti-Inflammatory Agents
📑 0.50 💥 0.50
open ⚖ 1500
With Neuroregeneration
📑 0.50 💥 0.50
open ⚖ 1500
Parkinson's Disease
📑 0.50 💥 0.50
open ⚖ 1500
Huntington's Disease
📑 0.50 💥 0.50
open ⚖ 1500
Prion Diseases
📑 0.50 💥 0.50
open ⚖ 1500
Antibody + small molecule
📑 0.50 💥 0.50
open ⚖ 1500
ASO + antibody
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy + cell therapy
📑 0.50 💥 0.50
open ⚖ 1500
Targeted protein degradation + immunotherapy
📑 0.50 💥 0.50
open ⚖ 1500
Brain shuttle technologies
📑 0.50 💥 0.50
open ⚖ 1500
Vectorized antibodies
📑 0.50 💥 0.50
open ⚖ 1500
RNA targeting beyond ASOs
📑 0.50 💥 0.50
open ⚖ 1500
Cellular rejuvenation
📑 0.50 💥 0.50
open ⚖ 1500
Genetic stratification
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-guided selection
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
CRISPR delivery
📑 0.50 💥 0.50
open ⚖ 1500
Regulatable systems
📑 0.50 💥 0.50
open ⚖ 1500
Gene Editing + Gene Therapy
📑 0.50 💥 0.50
open ⚖ 1500
CRISPR + Small Molecules
📑 0.50 💥 0.50
open ⚖ 1500
Ex Vivo Editing
📑 0.50 💥 0.50
open ⚖ 1500
Off-Target Detection
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Efficacy Markers
📑 0.50 💥 0.50
open ⚖ 1500
Subcutaneous levodopa
📑 0.50 💥 0.50
open ⚖ 1500
Improved formulations
📑 0.50 💥 0.50
open ⚖ 1500
Closed-loop systems
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy integration
📑 0.50 💥 0.50
open ⚖ 1500
Manufacturing scale-up
📑 0.50 💥 0.50
open ⚖ 1500
Engineered exosomes
📑 0.50 💥 0.50
open ⚖ 1500
Hybrid vesicles
📑 0.50 💥 0.50
open ⚖ 1500
Cell-specific targeting
📑 0.50 💥 0.50
open ⚖ 1500
Patient stratification
📑 0.50 💥 0.50
open ⚖ 1500
Treatment monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Dosing optimization
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Novel Agents
📑 0.50 💥 0.50
open ⚖ 1500
Onasemnogene abeparvovec ([onasemnogene-abeparvovec](/zolgensma-)))
📑 0.50 💥 0.50
open ⚖ 1500
Directional leads
📑 0.50 💥 0.50
open ⚖ 1500
Improved batteries
📑 0.50 💥 0.50
open ⚖ 1500
Wireless systems
📑 0.50 💥 0.50
open ⚖ 1500
PROTAC-mediated stabilization
📑 0.50 💥 0.50
open ⚖ 1500
Heterotypic condensates
📑 0.50 💥 0.50
open ⚖ 1500
LLPS modulators + kinase inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy + small molecules
📑 0.50 💥 0.50
open ⚖ 1500
Engineered exosomes
📑 0.50 💥 0.50
open ⚖ 1500
Optimized stimulation protocols
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-guided therapy
📑 0.50 💥 0.50
open ⚖ 1500
Chronic studies
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Targeted populations
📑 0.50 💥 0.50
open ⚖ 1500
Novel delivery
📑 0.50 💥 0.50
open ⚖ 1500
Adenosine A2A antagonists
📑 0.50 💥 0.50
open ⚖ 1500
GPR6 antagonists
📑 0.50 💥 0.50
open ⚖ 1500
Peripheral-restricted CB1 agonists
📑 0.50 💥 0.50
open ⚖ 1500
FAAH-sparing strategies
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-driven patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Disease stage optimization
📑 0.50 💥 0.50
open ⚖ 1500
Novel delivery systems
📑 0.50 💥 0.50
open ⚖ 1500
Oral brain-penetrant degraders
📑 0.50 💥 0.50
open ⚖ 1500
Multi-target degraders
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-guided development
📑 0.50 💥 0.50
open ⚖ 1500
Patient stratification
📑 0.50 💥 0.50
open ⚖ 1500
Triple-specific antibodies
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy combinations
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Therapeutics through bridging wiki connections. See all cross-field connections →

Cross-pollination from Genes 947 bridges →
Cross-pollination from Institutions 123 bridges →
Cross-pollination from Experiments 51 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map